Public Alert No. 039/2022 – Alert on Substandard (contaminated) paediatric cough syrups circulating in Gambia
October 7, 2022,
The National Agency for Food and Drugs Administration and Control (NAFDAC) is notifying Healthcare providers and the general public of four substandard products, identified in The Gambia and reported to WHO in September 2022.
The four products are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup.
Laboratory analysis of samples of the four products confirms that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants.
Diethylene glycol and ethylene glycol are toxic to humans when consumed and can prove fatal. Toxic effects can include abdominal pain, vomiting, diarrhoea, inability to pass urine, headache, altered mental state, and acute kidney injury which may lead to death.
The stated manufacturer of these products is Maiden Pharmaceuticals Limited (Haryana, India). To date, the stated manufacturer has not provided guarantees to WHO on the safety and quality of these products.
According to WHO, the four cold and cough syrups in question have been potentially linked with acute kidney injuries and 66 deaths among children in Gambia.
The details of the substandard cough syrups are as follows;
|Product Manufacture||Product Name|
|Maiden Pharmaceuticals Limited (Haryana, India)||· Promethazine Oral Solution,
· Kofexmalin Baby Cough Syrup,
· Makoff Baby Cough Syrup
· Magrip N Cold Syrup
All batches of these products listed above should be considered unsafe. The substandard products in this alert are unsafe and their use, especially in children, may result in serious injury or death.
The products are not registered by NAFDAC, therefore should not be in circulation.
To date, these four products have been identified in The Gambia, but may have been distributed, through informal markets, to other countries or regions.
NAFDAC implores importers, distributors, retailers and consumers to exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale and use of the substandard cough syrups. All medical products must be obtained from authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked.
Members of the public in possession of the above listed products are advised to discontinue sale or use and submit stock to the nearest NAFDAC office.
If you have these substandard products, please DO NOT use them. If you, or someone you know, have used these products or suffered any adverse reaction/event after use, you are advised to seek immediate medical advice from a qualified healthcare professional.
Healthcare professionals and consumers are encouraged to report any suspicion of adverse drug reaction and substandard and falsified medicines to NAFDAC on 0800-162-3322 or email: email@example.com